autologous XCART T-cells / Xenetic Biosci, Scripps Research Institute, Pharmsynthez - LARVOL DELTA

Xenetic Biosciences, Inc. Extends Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform (Xenetic Press Release) - "Xenetic Biosciences...announced it has extended its previously announced Research Funding and Option Agreement...with The Scripps Research Institute ('TSRI') to advance the development of the Company's program on the combination of systemic DNase and CAR T-cell therapies. Xenetic's systemic DNase I candidate is undergoing preclinical evaluation in combination with anti-CD19 CAR-T and anti-EGFR CAR-T cells in models of CD19-expressing hematological cancers and EGFR-expressing metastatic melanoma....Under the terms of the Scripps Research agreement, in addition to advancing Xenetic's existing intellectual property, Xenetic has an option to acquire an exclusive license to any new intellectual property arising from the DNase research program. Xenetic is executing on its plans to advance its DNase-based oncology program towards Phase 1 clinical development for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumors."

Licensing / partnership • Gastrointestinal Cancer • Hematological Malignancies • Melanoma • Oncology • Pancreatic Cancer • Skin Cancer

Xenetic Biosciences, Inc. Receives Notice of Allowance for XCART Patent (Xenetic Biosciences) - "Xenetic Biosciences...announced the United States Patent and Trademark Office (USPTO) has issued Xenetic a Notice of Allowance for U.S. patent application number 16/983,491 entitled, 'Articles and Methods Directed to Personalized Therapy of Cancer,' covering the co-administration of XCART-derived CAR T cells together with a personalized vaccine designed to enhance the effectiveness of the CAR T therapy....XCART is currently in pre-clinical development for the treatment of Non-Hodgkin lymphoma and progressing toward IND-enabling studies....This Notice of Allowance concludes the substantive examination of this patent application and will result in the issuance of a U.S. patent after administrative processes are completed. The U.S. patent scheduled to issue from this application will expire in 2038."

Patent • Hematological Malignancies • Non-Hodgkin’s Lymphoma • Oncology

Xenetic Biosciences, Inc. Reports Second Quarter 2021 Financial Results and Provides Business Update (Xenetic Biosciences) - "'Over the course of the second quarter, we continued to execute our innovative and differentiated XCART program, and the technical progress we've accomplished brings us closer to the critical milestone of conducting IND-enabling studies in the United States.'...Royalty payments of approximately $0.3 million were received in the quarter ended June 30, 2021 from the sublicense of the Company's partner, Takeda."

Clinical • Commercial • Hematological Malignancies • Non-Hodgkin’s Lymphoma • Oncology

Xenetic Biosciences, Inc. Reports First Quarter 2021 Financial Results (Xenetic Press Release) - "Collaboration with Pharmsynthez and multiple academic institutions in Eastern Europe to optimize the overall XCART™ workflow, including clinical manufacturing processes, and ultimately to conduct a first in human study in B-cell Non-Hodgkin lymphoma (NHL) patients; Recently commenced exploratory patient biopsy study in Eastern Europe. When sufficient experience is gained through this exploratory study, the collaborations being leveraged in the XCART™ development program may be expanded to include development and qualification of manufacturing processes for producing XCART™-designed, tumor-specific autologous CAR T cells; Upcoming Potential Milestones...Seeking U.S. FDA INTERACT meeting; Initiating process development for clinical CAR T manufacturing."

Clinical • FDA event • Licensing / partnership • Hematological Malignancies • Non-Hodgkin’s Lymphoma • Oncology

Xenetic Biosciences, Inc. Receives Approval to Commence Exploratory Study of XCART (Xenetic Press Release) - “Xenetic Biosciences…announced it has received approval to commence its exploratory patient biopsy study in Eastern Europe evaluating XCART…The exploratory study will be conducted at the Vitebsk Regional Clinical Oncological Center in Minsk, Belarus, and will enroll adult B-Cell NHL patients…We expect the data generated under this exploratory study to position the Company to conduct U.S. IND-enabling studies…”

Clinical • IND • Hematological Malignancies • Non-Hodgkin’s Lymphoma • Oncology

Xenetic Biosciences, Inc. to Present at NobleCon17 (Xenetic Press Release) - "Xenetic Biosciences, Inc...XCART™...announced today that Jeffrey Eisenberg, Chief Executive Officer of Xenetic will present at NobleCon17 - Noble Capital Markets' Seventeenth Annual Investor Conference on Tuesday, January 19, 2021 at 9:45 AM ET."

Clinical • Hematological Malignancies • Non-Hodgkin’s Lymphoma • Oncology

Xenetic Biosciences, Inc. to Present at the H.C. Wainwright BioConnect 2021 Virtual Conference (Xenetic Press Release) - "Xenetic Biosciences, Inc...announced today that Jeffrey Eisenberg, Chief Executive Officer of Xenetic will present in a fireside chat at the H.C. Wainwright BioConnect 2021 Virtual Conference taking place January 11-14, 2021."

Clinical • Oncology